Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare”) (NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostic company, today announced its results for the quarter ended September 30, 2026. Thyrocare reported consolidated revenue of INR 270.8 Cr in Q2FY27, up 25.1% year-on-year, driven primarily by a 26.7% increase in the Pathology segment.

Key Financial Highlights

Consolidated revenue registered a 25.1% year-on-year growth, driven primarily by a 26.7% increase in the Pathology segment. The exceptional item represents a one-time, non-cash impairment charge of Rs 45 Cr relating to NHL in consolidated books, recognised in connection with the definitive term sheet for the sale of the NHL business. This charge does not impact the Company’s operational performance.

Operational Performance

Thyrocare processed 61.6 million tests in Q2FY27, marking a strong 27.4% year-on-year growth and reinforcing its volume leadership position in the industry. The Pathology business maintained strong traction, with franchise revenue up 26.9% and partnership revenue up 27.9% year-on-year. Thyrocare’s commitment to quality continued to deliver Six Sigma-level performance, with complaints reduced to 2.9 per million (down 24% YoY) and an average turnaround time (ATAT) of 3.49 hours from sample receipt.

Future Outlook

Thyrocare continued its expansion into specialty diagnostics, marking the next phase of its growth journey. Having commenced with allergy and genomics, the Company is progressively expanding its specialty test portfolio, with a focus on building clinical trust through scientific rigour, uncompromising quality, and industry-leading turnaround times.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Thyrocare Technologies Limited

Thyrocare Technologies Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Thyrocare gains 42.8% over three months and trades near its 52-week highs. The business compounds revenue at 16.7% and profits at 36.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 87% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 16.7%, profits at 36.2%, and the PEG sits at 1.41 — below its growth rate. That combination is rare. Check Fundamentals of Thyrocare Technologies Limited.

Laurus Labs Limited (NSE: LAURUSLABS) has unveiled robust financial results for the first half of FY 2027, showcasing a significant revenue of ₹4,233 crore, marking a 31% year-on-year growth. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at ₹1,406 crore, reflecting a strong operational performance.

Strong Revenue and Margin Expansion

The company’s robust performance is driven by sustained growth in its Contract Development and Manufacturing Organization (CDMO) segment, which has seen commercial supplies and a steady momentum in its Affordable Medicines division. The gross margins expanded by over 3.3% points to 62.9%, supported by a healthy business segment mix.

Strategic Investments

Laurus Labs Limited has also announced strategic investments in two technology platforms to bolster its Integrated CDMO offering. The company has entered into a definitive agreement to acquire a 60% stake in Galenvs, a specialized firm in Oligonucleotide and Precision Magnetic Nanoparticles for purification. This acquisition aims to expand Laurus’s position in the fast-growing Oligo market, which is projected to reach $11 billion by 2030, with a CAGR of 22-24%.

Additionally, Laurus Labs plans to acquire a 52% stake in SI &C Resins, a company with expertise in peptide/polymer chemistry. This acquisition will enhance the company’s manufacturing competitiveness and reliability, particularly in the rapidly expanding GLP-1 and non-GLP-1 peptide drugs market.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Laurus Labs Limited

Laurus Labs Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Laurus gains 34.7% over three months and trades near its 52-week highs. The PEG stands at 25.45 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock trades at 98% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 34.7% in three months. Yet revenue grows at only 3.8% and the PEG stands at 25.45. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Laurus Labs Limited.

Max India Limited (MAXIND) has announced the completion of 200 homes at its Noida senior living community, Antara Noida, marking a significant milestone. The handover of these homes within less than two months of beginning the possession process underscores the company’s commitment to its integrated approach to senior living.

Integrated Senior Living Approach

Antara Senior Care, the senior-care business of Max India Limited, has completed the handover of 200 apartments at Antara Noida, its senior-living residential community in Sector 150, Noida. This achievement highlights the company’s dedication to providing a comprehensive ecosystem that combines purpose-designed residences with wellness, care, and lifestyle services.

Commitment to Senior Independence

Rajit Mehta, Managing Director & CEO of Antara Senior Living Limited and Max India, emphasized the company’s belief in senior living as more than just a place to live. ‘We believe that senior living should be about having the freedom to live life on one’s own terms, with the confidence that care and support are always within reach,’ said Mehta. The completion of 200 homes signifies a crucial step in this journey, reinforcing the company’s mission to build communities where seniors feel supported, inspired, and empowered.

Antara Noida, located in Sector 150, Noida, is a senior-living community with a total of 340 units designed to create an ecosystem where care evolves with the changing needs of seniors. The community aims to support seniors’ independence, wellbeing, and social connection through a blend of thoughtfully curated life care and lifestyle offerings.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max India Limited

Max India Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Max moves sideways over three months, with neither buyers nor sellers taking control. Industry-leading margins of 55.4% reflect exceptional pricing power and operational efficiency. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gains 13.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite -1.8% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Max India Limited.